Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States

9 references·1 citing·29 second hop

FromToDepth

this work references cited by second hop

References

2017Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13600 cited
2019Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval302 cited
2018A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics298 cited
2011Accelerated Approval of Oncology Products: The Food and Drug Administration Experience212 cited
2015From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients196 cited
2017Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration196 cited
2015Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study189 cited
2016Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014186 cited
2019New drugs: where did we go wrong and what can we do better?130 cited

Cited by

2024Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis85 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work